{"generic":"Flavocoxid","drugs":["Flavocoxid","Limbrel"],"mono":{"0":{"id":"jw2ms0","title":"Generic Names","mono":"Flavocoxid"},"1":{"id":"jw2ms1","title":"Dosing and Indications","sub":{"0":{"id":"jw2ms1b4","title":"Adult Dosing","mono":"<b>Osteoarthritis, for the clinical dietary management of the metobolic processess:<\/b> 250 mg ORALLY every 12 hours; may increase to 2 or more 250 mg tablets ever 12 hrs under physician supervision"},"1":{"id":"jw2ms1b5","title":"Pediatric Dosing","mono":"safety and efficacy in patients under 18 years of age have not been established "},"3":{"id":"jw2ms1b7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Osteoarthritis, for the clinical dietary management of the metobolic processess<br\/>"}}},"3":{"id":"jw2ms3","title":"Contraindications\/Warnings","sub":[{"id":"jw2ms3b9","title":"Contraindications","mono":"hypersensitivity to flavocoxid or to any component of the drug <br\/>"},{"id":"jw2ms3b10","title":"Precautions","mono":"<ul><li>flavocoxid is not a substitute for corticosteroid therapy and should not be used to treat corticosteroid deficiency<\/li><li>pregnant or lactating patients<\/li><li>stomach ulcers, history of<\/li><\/ul>"},{"id":"jw2ms3b11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"jw2ms3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"5":{"id":"jw2ms5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Cardiovascular:<\/b>Hypertension, exacerbation (2% or greater), Varicose vein finding (2% or greater)<\/li><li><b>Dermatologic:<\/b>Psoriasis (2% or greater)<\/li><\/ul>"},"6":{"id":"jw2ms6","title":"Drug Name Info","sub":{"0":{"id":"jw2ms6b17","title":"US Trade Names","mono":"Limbrel<br\/>"},"2":{"id":"jw2ms6b19","title":"Class","mono":"Nutriceutical<br\/>"},"3":{"id":"jw2ms6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jw2ms6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jw2ms7","title":"Mechanism Of Action","mono":"Flavocoxid, a specially formulated medical food product, maintains and restores the balance of fatty acids by dampening metabolism of amino acids (AA) as well as blocking the metabolism of AA by the 5- lipooxygenase enzymes. It also has a strong antioxidant activity through limitation of the oxidative conversion of AA by reactive oxygen species to other damaging fatty acid products.<br\/>"},"8":{"id":"jw2ms8","title":"Pharmacokinetics","sub":{"0":{"id":"jw2ms8b23","title":"Absorption","mono":"Effect of food: may increase absorption<br\/>"},"2":{"id":"jw2ms8b25","title":"Metabolism","mono":"Hepatic; P450; less than 10%, glucuronidation and sulfation <br\/>"}}},"9":{"id":"jw2ms9","title":"Administration","mono":"<b>Oral<\/b><br\/>may be safely taken with or without food <br\/>"},"10":{"id":"jw2ms10","title":"Monitoring","mono":"improved range of motion, decreased early morning stiffness and painful\/swollen joints, C-reactive protein levels, erythrocyte sedimentation rate<br\/>"},"11":{"id":"jw2ms11","title":"How Supplied","mono":"<b>Limbrel<\/b><br\/>Oral Capsule: 250 MG, 500 MG<br\/>"},"12":{"id":"jw2ms12","title":"Toxicology","sub":[{"id":"jw2ms12b31","title":"Clinical Effects","mono":"<b> FLAVOCOXID <\/b><br\/>OVERDOSE - Overdose data is limited. THERAPEUTIC ADVERSE EFFECTS - SERIOUS - Concurrent use of flavocoxid and NSAIDS or COX-2 inhibitors can cause gastrointestinal bleeding, ulceration and perforation. RARE - Increased varicose veins, hypertension, psoriasis and fluid accumulation in the knees have been reported rarely. <br\/>"},{"id":"jw2ms12b32","title":"Treatment","mono":"<b> FLAVOCOXID <\/b><br\/><ul><li>Decontamination: Severe toxicity is not expected after overdose of flavocoxid. Gastrointestinal decontamination is generally not necessary. Consider activated charcoal only after very large ingestions or if coingestants with significant toxicity are involved.<\/li><li>Support: Treatment is symptomatic and supportive.<\/li><li>Enhanced elimination procedure: There is no information regarding the effectiveness of hemodialysis or hemoperfusion for the removal of flavocoxid from plasma.<\/li><li>Monitoring of patient: Monitor vital signs in symptomatic patients.<\/li><\/ul>"},{"id":"jw2ms12b33","title":"Range of Toxicity","mono":"<b> FLAVOCOXID <\/b><br\/>OVERDOSE: Overdose data is limited. In animal studies, the administration of up to 20 times the recommended human dose (500 mg\/day) did not produce adverse events. THERAPEUTIC: Recommended adult dose is 250 mg every 12 hours; higher doses such as 250 mg three times a day may be used under a physician's supervision. <br\/>"}]}}}